Free Trial
NYSE:CHRO

Chromocell Therapeutics 5/15/2024 Earnings Report

Chromocell Therapeutics logo
$1.34 +0.08 (+6.35%)
Closing price 07/1/2025
Extended Trading
$1.34 0.00 (0.00%)
As of 07/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chromocell Therapeutics EPS Results

Actual EPS
-$5.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chromocell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chromocell Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Chromocell Therapeutics Earnings Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Ligand subsidiaries, Chromocell Therapeutics to merge
See More Chromocell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chromocell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chromocell Therapeutics and other key companies, straight to your email.

About Chromocell Therapeutics

Chromocell Therapeutics (NYSE:CHRO) is a clinical-stage biotechnology company focused on the development of autologous cell therapies for the treatment of peripheral nerve injury and degenerative neuropathies. Headquartered in Greater Boston, the company leverages proprietary technologies to isolate, expand and reinfuse patient-derived supportive cells, aiming to repair damaged nerves and restore function. Chromocell’s mission centers on addressing conditions for which there are currently limited or no effective therapeutic options, including chronic compressive lesions and diabetic neuropathy.

At the core of Chromocell’s pipeline is the OmniChrom™ cell manufacturing platform, designed to produce highly purified Schwann cell products with consistent potency and safety profiles. The lead clinical candidate, CHRO-101, is an autologous Schwann cell therapy being evaluated in Phase 1/2 trials for patients suffering from carpal tunnel syndrome and other compressive neuropathies. In parallel, preclinical programs seek to extend the platform’s potential to sensory and motor nerve injuries, leveraging transitional state Schwann cells to enhance nerve regeneration in both peripheral and, eventually, central nervous system indications.

Founded in 2018 as a spin-out from leading academic research institutions, Chromocell has since built a multidisciplinary team of experts in cell biology, neurology and scalable manufacturing. The company’s operations span the United States and Europe, working collaboratively with clinical sites and regulatory agencies to advance its cell therapy candidates. Under the guidance of a management team with decades of experience in biotech development and clinical translation, Chromocell Therapeutics aims to establish a new standard for regenerative medicine in neurodegenerative and nerve injury disorders.

View Chromocell Therapeutics Profile

More Earnings Resources from MarketBeat